Brenus Pharma Secures €22.2M Series A Funding to Advance Precision Cancer Vaccines

Brenus Pharma Secures €22.2M Series A Funding to Advance Precision Cancer Vaccines Lyon-based biotech firm Brenus Pharma has raised €22.2 million in a Series A funding round to advance its novel cancer vaccine platform, STC (Stimulated-Tumor-(ghost)-Cells). The round was led by Angelor, a regional investment fund, with participation from UI Investissement/Kreaxi, Crédit Agricole, Noshaq, Investsud, and existing investors. Key Takeaways: Innovative Cancer Vaccine Platform: Brenus Pharma develops immunotherapies that leverage the body's immune system to target and destroy cancer cells, focusing on preventing relapse. Their proprietary STC platform uses an in-depth understanding of cancer complexity to create personalized treatments. Funding Destination: The funding will primarily support the first-in-human clinical trials of their lead candidate, STC-1010, for metastatic colorectal cancer patients. The trials will focus on patients with resistance to existing immunotherapies. Expansion Plans: Beyond STC-1010, the company plans to expand the platform's application to other gastric tumors, including pancreatic and liver cancers. They are also developing STC-1020, their second vaccine candidate, for other solid tumor indications. Investor Confidence: Investors have expressed strong confidence in Brenus Pharma's potential to become a key player in the global precision immuno-oncology field. The company's innovative approach and experienced team were highlighted as key factors. Quotes: Jacques Gardette, Chairman of Bio Jag: "Brenus Pharma has taken a major step forward. [...] I’m convinced that the constant commitment and innovation of the Brenus team have built a solid foundation for tackling one of the world’s most complex therapeutic challenges." Marie Chambodut, Partner at Angelor: "We are proud to lead this strategic transaction for Brenus Pharma [...] We look forward to joining Paul and his exceptional team in transforming Brenus into a global player in precision immuno-oncology." Paul Bravetti, CEO of Brenus Pharma: "This is an important milestone for Brenus Pharma, confirming the potential of the STC platform, and of STC-1010 [...] Our shared ambition is to position our platform at the forefront of the national and international scene, and to become a leader in next-generation cancer immunotherapies.” Sources: EU-Startups: https://www.eu-startups.com/ Note: This briefing doc is based on the provided excerpts and may not capture the full scope of the news articles.